FTC Reaches Second Insulin Pricing Settlement: Comparing the Caremark and ESI Orders

The FTC settled its second major insulin pricing case against Caremark, requiring PBMs to delink rebates from formulary placement, cap patient out-of-pocket costs, and provide transparent cost reporting. The order mirrors an earlier ESI settlement but carves out Medicare, Medicaid, and Exchange plans from key requirements.

This Wire brief sits within Fusion42's coverage of Digital Health.